The US Food & Drug Administration’s inaugural class of applications for its START rare disease pilot program includes three early-stage gene therapy programs intended to treat pediatric diseases, including Rett syndrome (Neurogene), NGLY1 deficiency (Grace Science), and Canavan disease (Myrtelle).
The FDA announced the “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot last fall as offering an “Operation...








